Premium
The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin
Author(s) -
Sandler S. Gerald,
Novak Sharon C.,
Roland Barbara
Publication year - 2000
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(200003)63:3<156::aid-ajh9>3.0.co;2-4
Subject(s) - medicine , thrombocytopenic purpura , immune system , globulin , antibody , gamma globulin , immunology , rh isoimmunization , pregnancy , fetus , biology , genetics
Abstract Multiple factors, including efficacy, toxicity and cost, may influence the decision to treat immune thrombocytopenic purpura (ITP) with intravenous immune globulin (IVIG) or intravenous Rho (D) immune globulin (IV RhIG). We conducted a survey of 50 hospitals in 31 states to determine the costs for treating ITP using conventional doses for IVIG or IV RhIG, based on package insert recommendations. The average cost for a dose of IVIG ($2,771) was 71.7% ($1,157) more than that for a dose of IV RhIG ($1,614). In the absence of clearly defined differences in clinical outcomes when treating ITP with IVIG or IV RhIG, the difference in cost may be an important factor in selecting the treatment. Am J. Hematol. 63:156–158, 2000. © 2000 Wiley‐Liss, Inc.